SCHEMBL5651789

SCHEMBL5651789

CCOC(=O)c1sc2c(ccc(=O)n2-c2ccccc2)c1-c1ccccc1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
ALDH1A1 P00352 7/20 0.47
KMT2A Q03164 6/20 0.47
MEN1 O00255 5/20 0.47
GAA P10253 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 1/20 0.43
MDM2 Q00987 1/20 0.43
RECQL P46063 1/20 0.41
MAT2A P31153 1/20 0.41
KDM4E B2RXH2 2/20 0.40
MAPK1 P28482 1/20 0.38
NPC1 O15118 1/20 0.37
HPGD P15428 1/20 0.37
NFKB1 P19838 1/20 0.37
RAB9A P51151 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5648517 0.90 ALDH1A1 (0.50) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL5654208 0.90 MAPT (0.47) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL5649140 0.90 MAPT (0.47) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL5650462 0.90 MAPT (0.47) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL5649662 0.88 MAPT (0.43) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL5650136 0.88 MAPT (0.51) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL5650927 0.87 MAPT (0.44) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL5651888 0.87 MAPT (0.44) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL5653998 0.85 MAPT (0.48) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL16474394 0.84 MAPT (0.54) MAPTALDH1A1KMT2AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 MAPT 3795/4885ALDH1A1 1498/4885KMT2A 1815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.